TABLE 4.
Univariate associations between patient characteristics and clinical successa
| Clinical success (N = 121) | Clinical failure (N = 16) |
Odds ratio (95% CI) |
P value | |
|---|---|---|---|---|
| Age (years), mean (SD) | 59.1 (12.2) | 57.8 (14.7) | 1.01 (0.97–1.05) | 0.69 |
| Sex | ||||
| Female | 37 (30.6%) | 5 (31.3%) | 0.97 (0.31–2.99) | 0.96 |
| Male | 84 (69.4%) | 11 (68.8%) | Reference | |
| Height (cm), median (IQR) | 177 (168, 183) | 178 (170, 186) | 0.89 (0.53–1.52)b | 0.68 |
| Weight (kg), median (IQR) | 147.1 (131.6, 173.7) | 143.3 (129.6, 154.8) | 1.10 (0.91–1.32)b | 0.32 |
| BMI, median (IQR) | 49.3 (43.0, 57.1) | 44.9 (40.9, 55.1) | 1.04 (0.99–1.10) | 0.16 |
| Charlson comorbidity index, median (IQR) | 3 (2, 6) | 2 (2, 6) | 1.03 (0.87–1.22) | 0.74 |
| Albumin (g/dL), median (IQR) | ||||
| ≤2.5 | 26 (21.5%) | 8 (50.0%) | Reference | |
| >2.5 | 95 (78.5%) | 8 (50.0%) | 3.65 (1.25–10.67) | 0.018 |
| Ceftriaxone indication(s) | ||||
| Bacteremia | 42 (34.7%) | 4 (25.0%) | 1.60 (0.48–5.25) | 0.44 |
| Bone and joint infection | 22 (18.2%) | 4 (25.0%) | 0.67 (0.20–2.26) | 0.52 |
| Endocarditis | 5 (4.1%) | 3 (18.8%) | 0.19 (0.04–0.87) | 0.033 |
| Intra-abdominal infection | 11 (9.1%) | 0 (0.0%) | 3.43 (0.17–69.13) | 0.42 |
| Skin and soft tissue infection | 43 (35.5%) | 2 (12.5%) | 3.86 (0.84–17.78) | 0.083 |
| Urinary tract infection | 8 (6.6%) | 0 (0.0%) | 2.47 (0.12–53.22) | 0.56 |
| Pneumonia | 20 (16.5%) | 5 (31.3%) | 0.44 (0.14–1.39) | 0.16 |
| Number of ceftriaxone doses, median (IQR) | 10 (8, 14) | 10 (6, 15) | 1.04 (0.96–1.13) | 0.34 |
| Intensive care unit admission | 69 (57.0%) | 13 (81.3%) | 0.31 (0.08–1.13) | 0.076 |
a
BMI, body mass index; cm, centimeters; g/dL, grams per deciliter; IQR, interquartile range; kg, kilograms; SD, standard deviation.
b
Per 10 units.